p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease

Neuron

Volumn 47, Issue 1, 2005, Pages 29-41

  Bae, Byoung Il ^a   Xu, Hong ^a   Igarashi, Shuichi ^a   Fujimuro, Masahiro ^a   Agrawal, Nishant ^a   Taya, Yoichi ^b   Hayward, S Diane ^a   Moran, Timothy H ^a   Montell, Craig ^a   Ross, Christopher A ^a   Snyder, Solomon H ^a   Sawa, Akira ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; POLYGLUTAMINE; PROTEIN P53;

ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN TISSUE; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; GENE DELETION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MEMBRANE DEPOLARIZATION; MITOCHONDRION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; APOPTOSIS; BEHAVIOR; BEHAVIOR, ANIMAL; BLOTTING, NORTHERN; CELL SURVIVAL; DENSITOMETRY; DROSOPHILA; ELECTRON TRANSPORT; ESCAPE REACTION; GENE DELETION; GENES, REPORTER; HUMANS; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PLASMIDS; RETINAL DEGENERATION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21544450545     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2005.06.005     Document Type: Article

References (72)

1. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810
2. M.F. Beal Experimental models of Parkinson's disease Nat. Rev. Neurosci. 2 2001 325 334
3. M.F. Beal, E. Brouillet, B.G. Jenkins, R.J. Ferrante, N.W. Kowall, J.M. Miller, E. Storey, R. Srivastava, B.R. Rosen, and B.T. Hyman Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid J. Neurosci. 13 1993 4181 4192
4. D.L. Braff, M.A. Geyer, and N.R. Swerdlow Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies Psychopharmacology (Berl.) 156 2001 234 258
5. S.E. Browne, A.C. Bowling, U. MacGarvey, M.J. Baik, S.C. Berger, M.M. Muqit, E.D. Bird, and M.F. Beal Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia Ann. Neurol. 41 1997 646 653
6. T.R. Brummelkamp, R. Bernards, and R. Agami A system for stable expression of short interfering RNAs in mammalian cells Science 296 2002 550 553
7. R.J. Carter, L.A. Lione, T. Humby, L. Mangiarini, A. Mahal, G.P. Bates, S.B. Dunnett, and A.J. Morton Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation J. Neurosci. 19 1999 3248 3257
8. D. Chen, M. Li, J. Luo, and W. Gu Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function J. Biol. Chem. 278 2003 13595 13598
9. J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, N.M. Droin, D.D. Newmeyer, M. Schuler, and D.R. Green Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis Science 303 2004 1010 1014
10. J.K. Cooper, G. Schilling, M.F. Peters, W.J. Herring, A.H. Sharp, Z. Kaminsky, J. Masone, F.A. Khan, M. Delanoy, and D.R. Borchelt Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture Hum. Mol. Genet. 7 1998 783 790
11. J.N. Crawley What's Wrong with My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice 2000 Wiley-Liss New York
12. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
13. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356 1992 215 221
14. W. Duan, X. Zhu, B. Ladenheim, Q.S. Yu, Z. Guo, J. Oyler, R.G. Cutler, J.L. Cadet, N.H. Greig, and M.P. Mattson p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism Ann. Neurol. 52 2002 597 606
15. A.W. Dunah, H. Jeong, A. Griffin, Y.M. Kim, D.G. Standaert, S.M. Hersch, M.M. Mouradian, A.B. Young, N. Tanese, and D. Krainc Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease Science 296 2002 2238 2243
16. W.S. el-Deiry, S.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein Definition of a consensus binding site for p53 Nat. Genet. 1 1992 45 49
17. J. Gafni, and L.M. Ellerby Calpain activation in Huntington's disease J. Neurosci. 22 2002 4842 4849
18. J.L. Gonzalez de Aguilar, J.W. Gordon, F. Rene, M. de Tapia, B. Lutz-Bucher, C. Gaiddon, and J.P. Loeffler Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway Neurobiol. Dis. 7 2000 406 415
19. T. Grunewald, and M.F. Beal Bioenergetics in Huntington's disease Ann. N Y Acad. Sci. 893 1999 203 213
20. A.S. Hackam, R. Singaraja, C.L. Wellington, M. Metzler, K. McCutcheon, T. Zhang, M. Kalchman, and M.R. Hayden The influence of huntingtin protein size on nuclear localization and cellular toxicity J. Cell Biol. 141 1998 1097 1105
21. O. Hansson, E. Guatteo, N.B. Mercuri, G. Bernardi, X.J. Li, R.F. Castilho, and P. Brundin Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene Eur. J. Neurosci. 14 2001 1492 1504
22. B.A. Hay, T. Wolff, and G.M. Rubin Expression of baculovirus P35 prevents cell death in Drosophila Development 120 1994 2121 2129
23. M.O. Hebb, and H.A. Robertson Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases J. Comp. Neurol. 410 1999 99 114
24. J.G. Hodgson, N. Agopyan, C.A. Gutekunst, B.R. Leavitt, F. LePiane, R. Singaraja, D.J. Smith, N. Bissada, K. McCutcheon, and J. Nasir A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration Neuron 23 1999 181 192
25. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
26. S. Igarashi, H. Morita, K.M. Bennett, Y. Tanaka, S. Engelender, M.F. Peters, J.K. Cooper, J.D. Wood, A. Sawa, and C.A. Ross Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation Neuroreport 14 2003 565 568
27. G.R. Jackson, I. Salecker, X. Dong, X. Yao, N. Arnheim, P.W. Faber, M.E. MacDonald, and S.L. Zipursky Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons Neuron 21 1998 633 642
28. Y.H. Jiang, D. Armstrong, U. Albrecht, C.M. Atkins, J.L. Noebels, G. Eichele, J.D. Sweatt, and A.L. Beaudet Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation Neuron 21 1998 799 811
29. J. Jordan, M.F. Galindo, J.H. Prehn, R.R. Weichselbaum, M. Beckett, G.D. Ghadge, R.P. Roos, J.M. Leiden, and R.J. Miller p53 expression induces apoptosis in hippocampal pyramidal neuron cultures J. Neurosci. 17 1997 1397 1405
30. P. Kazemi-Esfarjani, and S. Benzer Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1 Hum. Mol. Genet. 11 2002 2657 2672
31. Y.J. Kim, Y. Yi, E. Sapp, Y. Wang, B. Cuiffo, K.B. Kegel, Z.H. Qin, N. Aronin, and M. DiFiglia Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis Proc. Natl. Acad. Sci. USA 98 2001 12784 12789
32. P.G. Komarov, E.A. Komarova, R.V. Kondratov, K. Christov-Tselkov, J.S. Coon, M.V. Chernov, and A.V. Gudkov A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy Science 285 1999 1733 1737
33. C., 4th Kuntz, Y. Kinoshita, L.A. Donehower, and R.S. Morrison Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis Exp. Neurol. 165 2000 184 190
34. S.H. Li, A.L. Cheng, H. Zhou, S. Lam, M. Rao, H. Li, and X.J. Li Interaction of Huntington disease protein with transcriptional activator Sp1 Mol. Cell. Biol. 22 2002 1277 1287
35. A.S. Mandir, C.M. Simbulan-Rosenthal, M.F. Poitras, J.R. Lumpkin, V.L. Dawson, M.E. Smulson, and T.M. Dawson A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism J. Neurochem. 83 2002 186 192
36. J.L. Marsh, H. Walker, H. Theisen, Y.Z. Zhu, T. Fielder, J. Purcell, and L.M. Thompson Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila Hum. Mol. Genet. 9 2000 13 25
37. K.S. McNaught, C.W. Olanow, B. Halliwell, O. Isacson, and P. Jenner Failure of the ubiquitin-proteasome system in Parkinson's disease Nat. Rev. Neurosci. 2 2001 589 594
38. T. Miyashita, and J.C. Reed Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 80 1995 293 299
39. R.S. Morrison, and Y. Kinoshita The role of p53 in neuronal cell death Cell Death Differ. 7 2000 868 879
40. R.S. Morrison, H.J. Wenzel, Y. Kinoshita, C.A. Robbins, L.A. Donehower, and P.A. Schwartzkroin Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death J. Neurosci. 16 1996 1337 1345
41. F.C. Nucifora Jr., M. Sasaki, M.F. Peters, H. Huang, J.K. Cooper, M. Yamada, H. Takahashi, S. Tsuji, J. Troncoso, and V.L. Dawson Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity Science 291 2001 2423 2428
42. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, and J.T. Greenamyre Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat. Neurosci. 5 2002 731 736
43. M.F. Peters, F.C. Nucifora Jr., J. Kushi, H.C. Seaman, J.K. Cooper, W.J. Herring, V.L. Dawson, T.M. Dawson, and C.A. Ross Nuclear targeting of mutant Huntingtin increases toxicity Mol. Cell. Neurosci. 14 1999 121 128
44. P.H. Reddy, M. Williams, V. Charles, L. Garrett, L. Pike-Buchanan, W.O. Whetsell Jr., G. Miller, and D.A. Tagle Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA Nat. Genet. 20 1998 198 202
45. Y.S. Rong, S.W. Titen, H.B. Xie, M.M. Golic, M. Bastiani, P. Bandyopadhyay, B.M. Olivera, M. Brodsky, G.M. Rubin, and K.G. Golic Targeted mutagenesis by homologous recombination in D. melanogaster Genes Dev. 16 2002 1568 1581
46. C.A. Ross Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders Neuron 35 2002 819 822
47. I. Sanchez, C. Mahlke, and J. Yuan Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 421 2003 373 379
48. T.K. Sang, C. Li, W. Liu, A. Rodriguez, J.M. Abrams, S.L. Zipursky, and G.R. Jackson Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis Hum. Mol. Genet. 14 2005 357 372
49. F. Saudou, S. Finkbeiner, D. Devys, and M.E. Greenberg Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95 1998 55 66
50. A. Sawa Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria? J. Mol. Med. 79 2001 375 381
51. A. Sawa, G.W. Wiegand, J. Cooper, R.L. Margolis, A.H. Sharp, J.F. Lawler Jr., J.T. Greenamyre, S.H. Snyder, and C.A. Ross Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization Nat. Med. 5 1999 1194 1198
52. A.H. Schapira Mitochondrial function in Huntington's disease: clues for pathogenesis and prospects for treatment Ann. Neurol. 41 1997 141 142
53. G. Schilling, M.W. Becher, A.H. Sharp, H.A. Jinnah, K. Duan, J.A. Kotzuk, H.H. Slunt, T. Ratovitski, J.K. Cooper, and N.A. Jenkins Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin Hum. Mol. Genet. 8 1999 397 407
54. G. Schilling, A.V. Savonenko, A. Klevytska, J.L. Morton, S.M. Tucker, M. Poirier, A. Gale, N. Chan, V. Gonzales, and H.H. Slunt Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice Hum. Mol. Genet. 13 2004 1599 1610
55. M.D. Shahbazian, H.T. Orr, and H.Y. Zoghbi Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion Neurobiol. Dis. 8 2001 974 981
56. N.E. Sharpless, and R.A. DePinho p53: good cop/bad cop Cell 110 2002 9 12
57. T. Shimohata, T. Nakajima, M. Yamada, C. Uchida, O. Onodera, S. Naruse, T. Kimura, R. Koide, K. Nozaki, and Y. Sano Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription Nat. Genet. 26 2000 29 36
58. S. Sipione, D. Rigamonti, M. Valenza, C. Zuccato, L. Conti, J. Pritchard, C. Kooperberg, J.M. Olson, and E. Cattaneo Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses Hum. Mol. Genet. 11 2002 1953 1965
59. S.S. Sisodia Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell 95 1998 1 4
60. S.A. Sorensen, K. Fenger, and J.H. Olsen Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract? Cancer 86 1999 1342 1346
61. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, H. Gohler, E.E. Wanker, G.P. Bates, D.E. Housman, and L.M. Thompson The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc. Natl. Acad. Sci. USA 97 2000 6763 6768
62. N.R. Swerdlow, J. Paulsen, D.L. Braff, N. Butters, M.A. Geyer, and M.R. Swenson Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease J. Neurol. Neurosurg. Psychiatry 58 1995 192 200
63. S.J. Tabrizi, M.W. Cleeter, J. Xuereb, J.W. Taanman, J.M. Cooper, and A.H. Schapira Biochemical abnormalities and excitotoxicity in Huntington's disease brain Ann. Neurol. 45 1999 25 32
64. S.J. Tabrizi, J. Workman, P.E. Hart, L. Mangiarini, A. Mahal, G. Bates, J.M. Cooper, and A.H. Schapira Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Ann. Neurol. 47 2000 80 86
65. A.J. Tobin, and E.R. Signer Huntington's disease: the challenge for cell biologists Trends Cell Biol. 10 2000 531 536
66. F. Trettel, D. Rigamonti, P. Hilditch-Maguire, V.C. Wheeler, A.H. Sharp, F. Persichetti, E. Cattaneo, and M.E. MacDonald Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells Hum. Mol. Genet. 9 2000 2799 2809
67. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
68. C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, and N. Thornberry Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells J. Biol. Chem. 275 2000 19831 19838
69. V.C. Wheeler, J.K. White, C.A. Gutekunst, V. Vrbanac, M. Weaver, X.J. Li, S.H. Li, H. Yi, J.P. Vonsattel, and J.F. Gusella Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice Hum. Mol. Genet. 9 2000 503 513
70. H. Xu, S.J. Lee, E. Suzuki, K.D. Dugan, A. Stoddard, H.S. Li, L.A. Chodosh, and C. Montell A lysosomal tetraspanin associated with retinal degeneration identified via a genome-wide screen EMBO J. 23 2004 811 822
71. J. Yu, L. Zhang, P.M. Hwang, K.W. Kinzler, and B. Vogelstein PUMA induces the rapid apoptosis of colorectal cancer cells Mol. Cell 7 2001 673 682
72. M.M. Zeron, O. Hansson, N. Chen, C.L. Wellington, B.R. Leavitt, P. Brundin, M.R. Hayden, and L.A. Raymond Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease Neuron 33 2002 849 860